Navigation Links
Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals
Date:8/14/2014

DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in fiscal 2015.

The merger follows strong approval by both Mallinckrodt and Questcor shareholders at separate special meetings held today. Under the terms of the merger agreement, Questcor shareholders will receive $30.00 in cash and 0.897 of a Mallinckrodt ordinary share for each Questcor share.

"We are pleased to complete this transformative transaction and believe it will provide a strong, durable, well-diversified and sustainable platform, capable of generating significant future revenue and earnings growth for Mallinckrodt shareholders," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. "HP Acthar® Gel has demonstrated success in treating patients suffering from a variety of devastating and difficult-to-treat autoimmune and inflammatory illnesses. We are confident that Acthar will be a strong complement to Mallinckrodt's broadening portfolio of leading specialty pharmaceutical brands, and we look forward to leveraging our extensive manufacturing and scientific expertise, as well as our experience with advocacy and payer communities, to capitalize on the many opportunities it presents."

Mr. Trudeau added, "We are very pleased to welcome the Questcor team to Mallinckrodt. We are excited about our future
'/>"/>

SOURCE Mallinckrodt plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
3. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
6. CryoLife Completes Acquisition of Hemosphere
7. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
8. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
9. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
10. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
11. Ablative Solutions Completes $5.3M Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Biomedical Inc. ( www.synapsebiomedical.com ) announced today it ... of its NeuRx DPS® System for ALS patients.  ... enrollment requirement was implanted over a month and ... which is the only medical device approved by ... humanitarian device that obtained approval at the end ...
(Date:9/30/2014)... EXECUTIVE SUMMARY The present report ... - Increasing Demand from Ageing Population to Drive ... past, present and future outlook. The report discusses ... market with outlook to 2017. Statistics include functional ... sub-segments of the industry, ongoing trends and developments, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
(Date:9/30/2014)... at the University of Michigan have described a new ... fraction of the time needed for more traditional methods. ... novel antibody that is undergoing further investigation as a ... , In research published online in the ... researchers in the lab of Stephen Weiss at the ...
(Date:9/30/2014)... Fla. (PRWEB) September 30, 2014 Lea ... is giving breast cancer patients a new, more practical ... , Women who undergo mastectomies, biopsies and lumpectomy surgeries ... promote healing. But after seeing her patients describe the ... compelled to create a new bra in her spare ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Brig Hart, ... history, who broke over 500 Diamond-ranked professionals using his ... doing it again. The Life Support System for ... he has been perfecting using his experiences and successes ... month. Using the principles and methodology taught by Brig ...
(Date:9/30/2014)... Farmington, NY (PRWEB) September 30, 2014 Timber ... design/build process for the Olsen family’s reclaimed Douglas fir ... will cover the home’s journey from architectural planning, to the ... Dee Olsen turned to New Energy Works, after following the ... to design and build their dream vacation home on land ...
(Date:9/30/2014)... September 30, 2014 ... , From:        Hope For The ... abarnwell(at)hopeforthewarriors(dot)org , Event:        Got ... , Date:        Thursday, October 2, ... and Navy Club, 901 ...
Breaking Medicine News(10 mins):Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 2Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... , , ... US Oncology, Inc . today announced that US Oncology ... Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or ... HER2-negative metastatic breast cancer. , , ...
... , , , , ... its online boutique, www.chemo-couture.com , featuring inspirational, handcrafted ... and loved ones. , , Inspired ... disease, Jane Bebita and Julie Uhrig joined forces to create an ...
... , , SEOUL, South Korea, July ... 039350) is pleased to announce that its wholly owned subsidiary, ... for the commercial, institutional, and consumer markets, has successfully turned the ... the world) green! Royal Laundry of South San Francisco ...
... , , , ... Resources, one of the world,s leading research and advisory firms focusing ... market in Brazil will grow from $200 million in 2008 to ... the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott,s Humira and Schering-Plough,s Remicade ...
... , , BRIDGEWATER, N.J., ... that it is possible to recruit large numbers of women, ... The study, known as GRACE, is the largest study to ... and race differences in response to an HIV-1 therapy -- ...
... , WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July ... FORMA Therapeutics today announced a partnership to accelerate LLS,s pipeline of ... , The collaboration will begin with a selection of ... to have the most promise of advancing into clinical trials in ...
Cached Medicine News:Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 2Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 3Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 3Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 4Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 5Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 6Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 7Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 8Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
Medicine Products: